Search
for
Sort by
Research 241–270 of 1000+
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
- Janus Kinase Inhibitors - A next generation treatment in Dermatology
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
- <i>In‐silico</i> Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its <i>In‐vitro</i> Evaluation
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- Topical Janus kinase inhibitors: A review of applications in dermatology
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
- 72751 Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review
- P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- “<i>Nomen Omen</i>: The Myth of God Janus”
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Alopecia areata
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Leptin and the skin: a new frontier
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
- Tofacitinib for the treatment of lichen planopilaris: A case series